HK Stock Market Move | ABBISKO-B (02256) rises more than 6%, the company achieved profits for the second consecutive year, with strong commercialization expectations for its core product, Bejet Mile.

ABBISKO-B (02256) rose more than 6%, up 5.63% as of press time, closing at HK$11.64, with a turnover of HK$147.042 million. In terms of news, recently, ABBISKO-B released its annual performance for the year ending December 31, 2025. The group achieved a revenue of RMB 612 million, a year-on-year increase of 21.45%; the comprehensive income attributable to the parent company's owners was RMB 23.698 million, a year-on-year decrease of 53.46%; and the basic earnings per share were RMB 0.09. The group achieved profitability for the second consecutive year. For the year ending December 31, 2025, the group had revenue of RMB 612.1 million (from the royalties received from Merck), and a profit of RMB 55.2 million. In the report "ABBISKO-B (02256): Annual Report Releases Continued Profit Signals, Commercialization Begins the Year of Full Growth", it is pointed out that looking forward to 2026, with the global first new drug application of the core product Bejima (Pimethide hydrochloride capsules) approved domestically, Huyu will enter the first year of commercialization, and will also enter a new value cycle of "hardcore innovation-commercialization realization-performance verification". With strong commercialization expectations for Bejima, a significant net cash position for Huyu can be expected, thus propelling the company's innovative research and development onto a new level and laying a solid foundation for continued upward valuation of the company in the future.